Jean-Baptiste Lattouf1, Stephen E Pautler2, M Neil Reaume3, Raymond H Kim4, Melanie Care5, Jane Green6, Alan So7, Philippe D Violette8, Issam Saliba9, Philippe Major10, Shane Silver11, Richard Leicht12, Joan Basiuk13, Simon Tanguay14, Michael A S Jewett15, Darrel Drachenberg16. 1. Division of Urology, Department of Surgery, University of Montreal Hospital Centre, Montreal, QC, Canada. 2. Divisions of Urology and Surgical Oncology, Departments of Surgery and Oncology, Western University, London, ON, Canada. 3. Division of Medical Oncology, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada. 4. Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. 5. Fred A. Litwin Family Centre in Genetic Medicine, University Health Network & Mount Sinai Hospital, Toronto, ON, Canada. 6. Disciplines of Genetics and Medicine, Faculty of Medicine, Memorial University of Newfoundland, St. John's, NL, Canada. 7. Department of Urologic Sciences, Faculty of Medicine, Vancouver General Hospital and University of British Columbia, Vancouver, BC, Canada. 8. Division of Urology, Department of Surgery, Woodstock General Hospital, Woodstock, ON, Canada. 9. Division of ENT, Department of Surgery, University of Montreal Hospital Centre, Montreal, QC, Canada. 10. CHU Sainte-Justine, Department of Neurosciences, University of Montreal, Montreal, QC, Canada. 11. Faculty of Medicine and the Division of Dermatology, University of Manitoba, Winnipeg, MB, Canada. 12. Department of Ophthalmology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada. 13. Kidney Cancer Research Network of Canada, Toronto, ON, Canada. 14. Division of Urology, McGill University, Montreal, QC, Canada. 15. Division of Urology, Departments of Surgical Oncology and Surgery, Princess Margaret Cancer Centre and the University Health Network, University of Toronto, Toronto, ON, Canada. 16. Section of Urology, Department of Surgery, University of Manitoba, Winnipeg, MB, Canada.
Abstract
INTRODUCTION: Optimal clinical assessment and subsequent followup of patients with or suspected of having a hereditary renal cell carcinoma syndrome (hRCC) is not standardized and practice varies widely. We propose protocols to optimize these processes in patients with hRCC to encourage a more uniform approach to management that can then be evaluated. METHODS: A review of the literature, including existing guidelines, was carried out for the years 1985-2015. Expert consensus was used to define recommendations for initial assessment and followup. RESULTS: Recommendations for newly diagnosed patients' assessment and optimal ages to initiate followup protocols for von Hippel Lindau disease (VHL), hereditary papillary renal cancer (HPRC), hereditary leiomyomatosis with renal cell carcinoma (HLRCC), Birt-Hogg-Dubé syndrome (BHD), familial paraganglioma-pheochromocytoma syndromes (PGL-PCC), and tuberous sclerosis (TSC) are proposed. CONCLUSIONS: Our proposed consensus for structured assessment and followup is intended as a roadmap for the care of patients with hRCC to guide healthcare providers. Although the list of syndromes included is not exhaustive, the document serves as a starting point for future updates.
INTRODUCTION: Optimal clinical assessment and subsequent followup of patients with or suspected of having a hereditary renal cell carcinoma syndrome (hRCC) is not standardized and practice varies widely. We propose protocols to optimize these processes in patients with hRCC to encourage a more uniform approach to management that can then be evaluated. METHODS: A review of the literature, including existing guidelines, was carried out for the years 1985-2015. Expert consensus was used to define recommendations for initial assessment and followup. RESULTS: Recommendations for newly diagnosed patients' assessment and optimal ages to initiate followup protocols for von Hippel Lindau disease (VHL), hereditary papillary renal cancer (HPRC), hereditary leiomyomatosis with renal cell carcinoma (HLRCC), Birt-Hogg-Dubé syndrome (BHD), familial paraganglioma-pheochromocytoma syndromes (PGL-PCC), and tuberous sclerosis (TSC) are proposed. CONCLUSIONS: Our proposed consensus for structured assessment and followup is intended as a roadmap for the care of patients with hRCC to guide healthcare providers. Although the list of syndromes included is not exhaustive, the document serves as a starting point for future updates.
Authors: L Schmidt; K Junker; G Weirich; G Glenn; P Choyke; I Lubensky; Z Zhuang; M Jeffers; G Vande Woude; H Neumann; M Walther; W M Linehan; B Zbar Journal: Cancer Res Date: 1998-04-15 Impact factor: 12.701
Authors: P L Choyke; M M Walther; G M Glenn; J R Wagner; D J Venzon; I A Lubensky; B Zbar; W M Linehan Journal: J Comput Assist Tomogr Date: 1997 Sep-Oct Impact factor: 1.826
Authors: Fred H Menko; Maurice A M van Steensel; Sophie Giraud; Lennart Friis-Hansen; Stéphane Richard; Silvana Ungari; Magnus Nordenskjöld; Thomas Vo Hansen; John Solly; Eamonn R Maher Journal: Lancet Oncol Date: 2009-12 Impact factor: 41.316
Authors: Russell R Lonser; Gladys M Glenn; McClellan Walther; Emily Y Chew; Steven K Libutti; W Marston Linehan; Edward H Oldfield Journal: Lancet Date: 2003-06-14 Impact factor: 79.321
Authors: Mary B Daly; Robert Pilarski; Jennifer E Axilbund; Saundra S Buys; Beth Crawford; Susan Friedman; Judy E Garber; Carolyn Horton; Virginia Kaklamani; Catherine Klein; Wendy Kohlmann; Allison Kurian; Jennifer Litton; Lisa Madlensky; P Kelly Marcom; Sofia D Merajver; Kenneth Offit; Tuya Pal; Boris Pasche; Gwen Reiser; Kristen Mahoney Shannon; Elizabeth Swisher; Nicoleta C Voian; Jeffrey N Weitzel; Alison Whelan; Georgia L Wiesner; Mary A Dwyer; Rashmi Kumar Journal: J Natl Compr Canc Netw Date: 2014-09 Impact factor: 11.908
Authors: Christopher J Ricketts; Brian Shuch; Cathy D Vocke; Adam R Metwalli; Gennady Bratslavsky; Lindsay Middelton; Youfeng Yang; Ming-Hui Wei; Stephen E Pautler; James Peterson; Catherine A Stolle; Berton Zbar; Maria J Merino; Laura S Schmidt; Peter A Pinto; Ramaprasad Srinivasan; Karel Pacak; W Marston Linehan Journal: J Urol Date: 2012-10-18 Impact factor: 7.450
Authors: Patrick O Richard; Philippe D Violette; Bimal Bhindi; Rodney H Breau; Wassim Kassouf; Luke T Lavallée; Michael Jewett; John R Kachura; Anil Kapoor; Maxine Noel-Lamy; Michael Ordon; Stephen E Pautler; Frédéric Pouliot; Alan I So; Ricardo A Rendon; Simon Tanguay; Christine Collins; Maryam Kandi; Bobby Shayegan; Andrew Weller; Antonio Finelli; Andrea Kokorovic; Jay Nayak Journal: Can Urol Assoc J Date: 2022-02 Impact factor: 1.862
Authors: Raymond H Kim; Xiangling Wang; Andrew J Evans; Steven C Campbell; Jane K Nguyen; Kirsten M Farncombe; Charis Eng Journal: NPJ Genom Med Date: 2020-09-29 Impact factor: 8.617
Authors: A Beatriz Sánchez-Heras; Adela Castillejo; Juan D García-Díaz; Mercedes Robledo; Alexandre Teulé; Rosario Sánchez; Ángel Zúñiga; Enrique Lastra; Mercedes Durán; Gemma Llort; Carmen Yagüe; Teresa Ramon Y Cajal; Consol López San Martin; Adrià López-Fernández; Judith Balmaña; Luis Robles; José M Mesa-Latorre; Isabel Chirivella; María Fonfria; Raquel Perea Ibañez; M Isabel Castillejo; Inés Escandell; Luis Gomez; Pere Berbel; Jose Luis Soto Journal: Cancers (Basel) Date: 2020-11-05 Impact factor: 6.639